Last reviewed · How we verify
RAY1216 dose 4 &ritonavir
At a glance
| Generic name | RAY1216 dose 4 &ritonavir |
|---|---|
| Sponsor | Guangdong Raynovent Biotech Co., Ltd |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- The Safety, Tolerability and Pharmacokinetics Study of RAY1216 in Healthy Adult Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RAY1216 dose 4 &ritonavir CI brief — competitive landscape report
- RAY1216 dose 4 &ritonavir updates RSS · CI watch RSS
- Guangdong Raynovent Biotech Co., Ltd portfolio CI